The intermittent intrapulmonary deflation technique for airway clearance in patients with cystic fibrosis: A randomized trial

Respir Med Res. 2024 Nov:86:101094. doi: 10.1016/j.resmer.2024.101094. Epub 2024 Feb 29.

Abstract

Background: Cystic fibrosis (CF) is a muco-obstructive lung disease characterized by thick sputum with abnormal rheological properties. The intermittent intrapulmonary deflation (IID) is a new instrumental airway clearance technique (ACT) that aims to decrease the sputum viscoelastic properties. This study assessed the benefits of adding the IID technique to a conventional ACT in patients with CF hospitalized for intravenous antibiotic therapy.

Methods: Participants with CF accustomed to autogenic drainage (AD) as their standard ACT received, in a randomized order, a 30-min session of either AD alone or AD combined with IID (AD+IID). Sputum was collected during each ACT regimens and for a 24-hour period following both sessions. Sputum wet weight, dry weight, solids content and rheological properties were analyzed. Cough events occurring during and over 2 h post ACT were compared between both regimens.

Results: Seventeen patients with CF (aged 29 ± 11 years; FEV1%: 57.1 ± 20.1) were analysed. The sputum wet weight collected during AD alone was significantly higher than during AD+IID (8.11 ± 6.93 vs 5.40 ± 4.11 respectively, p = 0.01). The sputum rheological properties did not significantly differ between group. There were more cough episodes during AD alone compared to AD+IID (median [IQR]: 8 [5-15.5] vs 5 [3.5-11.0] respectively, p = 0.02).

Conclusions: In participants with CF accustomed to AD, adding the IID technique in combination to AD does not confer a clear benefit on airway clearance in the short term. Clinical Trials register: NCT04157972.

Keywords: Airway clearance technique; Cystic fibrosis; Intermittent intrapulmonary deflation; Mucus and sputum; Rheology; Simeox.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Anti-Bacterial Agents / administration & dosage
  • Cough / etiology
  • Cystic Fibrosis* / complications
  • Cystic Fibrosis* / physiopathology
  • Cystic Fibrosis* / therapy
  • Female
  • Humans
  • Male
  • Respiratory Therapy / methods
  • Sputum*
  • Young Adult

Substances

  • Anti-Bacterial Agents

Associated data

  • ClinicalTrials.gov/NCT04157972